|Title:||Methods and compositions for inhibition of angiogenesis|
|Abstract:||The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis. Importantly, these compounds can be administered orally.|
|Inventor(s):||D'Amato; Robert (Lancaster, PA)|
|Assignee:||Childrens Hospital Medical Center Corp. (Boston, MA)|
1. A method of treating undesired angiogenesis in a human or animal comprising, administering to the human or animal with the undesired angiogenesis a composition comprising an
angiogenesis-inhibiting amount of thalidomide.
2. The method of claim 1, wherein the composition further comprises an epoxide hydrolase inhibitor.
3. The method of claim 1, wherein the undesired angiogenesis is associated with corneal neovascularization.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.